SOPHiA GENETICS SA Ordinary Shares
SOPHSOPHiA GENETICS SA is a global leader in data-driven medicine, specializing in using artificial intelligence and computational biology to analyze complex healthcare data. The company provides a cloud-based platform that enables healthcare professionals and researchers to share, analyze, and interpret genomic and clinical data for improved diagnosis, treatment, and research in precision medicine. Founded in Switzerland, SOPHiA GENETICS aims to advance healthcare through collaborative data sharing and innovative technology.
Company News
U.S. stock futures showed mixed performance on Wednesday with the Dow Jones declining while the S&P 500 and Nasdaq 100 advanced. Investors awaited the FOMC interest rate decision expected at 2:00 p.m. ET, with markets pricing a 99.6% likelihood of unchanged rates. Notable movers included La-Z-Boy surging 19.62% on strong earnings and a $300 milli...
The artificial intelligence in diagnostics market is projected to grow at a CAGR of 22.2% from 2024 to 2032, driven by the rising prevalence of chronic diseases and the increasing demand for AI tools in disease diagnosis.
Shareholders adopt all proposals at Annual General Meeting Shareholders adopt all proposals at Annual General Meeting
CoreWeave, a company backed by Nvidia, is preparing to go public in 2025.
The average of price targets set by Wall Street analysts indicates a potential upside of 65% in SOPHiA GENETICS (SOPH). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
